January 18, 2011
ParaPRO, LLC announced today that the U.S. Food and Drug Administration (FDA) has approved Natroba™ (spinosad) Topical Suspension, 0.9% to
eliminate head lice (pediculosis capitis).
Read the full press release
July 26, 2010
The American Academy of Pediatrics released their Updated Head Lice Report in the online version of Pediatrics earlier this week. Key points include a call to abandon school No Nit Policies , pediatricians are encouraged to take an active role in diagnosis and providing information, diagnosis needs to be confirmed before treatment and treatments should have a clinical record of efficacy and safety for consideration.
Read the full story
Ask your doctor if Natroba Topical Suspension is right for you or your child.
INDICATION
Natroba Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients four (4) years of age and older.
IMPORTANT SAFETY INFORMATION
Natroba Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic
exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants.
Most common adverse events were: application site redness (3%), redness and irritation of the eyes (2%) and application site irritation (1%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.